PreveCeutical Medical Inc. announced the incorporation of its first Australian wholly-owned subsidiary, PreveCeutical (Australia) Pty Ltd, as part of an expansion of the company's business in Brisbane, Australia. The decision to incorporate the company's first subsidiary in Australia was influenced by Australia's strong foundation of academic and clinical research, as well as the Australian government's commitment to supporting innovation through a range of programs and incentives. Such incentives include the research and development (R&D) tax incentive, whereby the Australian government encourages companies to engage in R&D benefiting Australia by providing a tax offset for eligible R&D activities. The current annual refundable tax offset under the program is 43.5%.

PreveCeutical's new Australian team, led by Director of International Operations, Dr. Maher Khaled, will work closely with the company's Chief Research Officer, Dr. Harry Parekh, to advance the development of the company's therapeutic technologies. Management of the Company's Australian subsidiary includes the following individuals: Stephen Van Deventer - Chairman and Director: Mr. Van Deventer is an experienced businessman and corporate director. Specialising in international corporate relations and business development over the last twenty-five years, Mr. Van Deventer has focused on launching small to medium-sized companies into the public markets in Canada, the United States and Europe. He has also owned and operated private businesses. Maher Khaled - PhD, LLB, BSc - Chief Executive Officer, Secretary and Director: Dr. Khaled has spent over a decade commercializing therapeutic and diagnostic technologies developed at the University of Queensland and the University of Cambridge, United Kingdom, while working at UniQuest Pty Ltd. Prior to his work at UniQuest, Dr. Khaled was an investment manager at Cambridge Enterprise Seed Funds. While at Cambridge, Dr. Khaled directed the investment ofseed capital in start-up companies, and in some of which also held directorships. He also advised pharmaceutical and medical device companies on strategic and operational issues while working at McKinsey & Company's London office. Kimberly Van Deventer - Director: Ms. Van Deventer is an entrepreneur with a successful track record of accomplishment that she has brought to PreveCeutical. Ms. Van Deventer is a driving force behind PreveCeutical and unwavering in her commitment to raising awareness about health and disease prevention. Shabira Rajan, MBA, CPA, CGA - Chief Financial Officer: Ms. Rajan is a senior financial executive with over 20 years of experience, leading the financial discipline for successful businesses in both private and public sectors. She has a track record of providing leadership for strategic value creation and continuous improvement, as well as providing effective direction to organizations on issues relating to corporate governance, financial oversight and risk management. One of her past leadership roles was that of Director of Finance at Canada Line Rapid Transit Inc., which planned and constructed a $2 billion rapid transit system in metro-Vancouver, on time and within budget.